Mistletoe in the treatment of malignant melanoma

Malignant melanoma is a malignant neoplasia drives from melanocytes. Malignant melanoma, the most causing death, is seen in the third place at skin cancer. Malignant melanoma shows intrinsic resistance to chemotherapeutic agents and variability in the course of the disease which are distinct feature...

Full description

Bibliographic Details
Main Authors: Esin Sakallı Çetin, Pınar Aslan Koşar, Nurten Özçelik
Format: Article
Language:English
Published: Modestum Publishing LTD 2014-03-01
Series:Journal of Clinical and Experimental Investigations
Subjects:
Online Access:http://www.jceionline.org/upload/sayi/20/JCEI-00859.pdf
id doaj-041ccef1940d4c029ba230dc801995e0
record_format Article
spelling doaj-041ccef1940d4c029ba230dc801995e02021-09-02T04:32:18ZengModestum Publishing LTDJournal of Clinical and Experimental Investigations1309-85781309-66212014-03-015114515210.5799/ahinjs.01.2014.01.0380Mistletoe in the treatment of malignant melanomaEsin Sakallı Çetin0Pınar Aslan Koşar1Nurten Özçelik2Department of Medical Biology, School of Medicine, Muğla Sıtkı Koçman University, 48100, Muğla, TurkeyDepartment of Medical Biology, School of Medicine, Süleyman Demirel University, 32260, Isparta, TurkeyDepartment of Medical Biology, School of Medicine, Süleyman Demirel University, 32260, Isparta, TurkeyMalignant melanoma is a malignant neoplasia drives from melanocytes. Malignant melanoma, the most causing death, is seen in the third place at skin cancer. Malignant melanoma shows intrinsic resistance to chemotherapeutic agents and variability in the course of the disease which are distinct features separating from other solid tumors. These features prevent the development and standardization of non-surgical treatment models of malignant melanoma. Although there is a large number of chemotherapeutic agents used in the treatment of metastatic malignant melanoma, it hasn’t been demonstrated the survival advantage of adjuvant treatment with chemotherapeutic agents. Because of the different clinical course of malignant melanoma, the disease is thought to be closely associated with immune system. Therefore, immunomodulatory therapy models were developed. Mistletoe stimulates the immune system by increasing the number and activity of dendritic cells, thus it has been shown to effect on tumor growth and metastasis of malignant melanoma patient. Outlined in this review are the recent developments in the understanding the role of mistletoe as a complementary therapy for malignant melanoma. J Clin Exp Invest 2014; 5 (1): 145-152http://www.jceionline.org/upload/sayi/20/JCEI-00859.pdfMalignant melanomamistletoe
collection DOAJ
language English
format Article
sources DOAJ
author Esin Sakallı Çetin
Pınar Aslan Koşar
Nurten Özçelik
spellingShingle Esin Sakallı Çetin
Pınar Aslan Koşar
Nurten Özçelik
Mistletoe in the treatment of malignant melanoma
Journal of Clinical and Experimental Investigations
Malignant melanoma
mistletoe
author_facet Esin Sakallı Çetin
Pınar Aslan Koşar
Nurten Özçelik
author_sort Esin Sakallı Çetin
title Mistletoe in the treatment of malignant melanoma
title_short Mistletoe in the treatment of malignant melanoma
title_full Mistletoe in the treatment of malignant melanoma
title_fullStr Mistletoe in the treatment of malignant melanoma
title_full_unstemmed Mistletoe in the treatment of malignant melanoma
title_sort mistletoe in the treatment of malignant melanoma
publisher Modestum Publishing LTD
series Journal of Clinical and Experimental Investigations
issn 1309-8578
1309-6621
publishDate 2014-03-01
description Malignant melanoma is a malignant neoplasia drives from melanocytes. Malignant melanoma, the most causing death, is seen in the third place at skin cancer. Malignant melanoma shows intrinsic resistance to chemotherapeutic agents and variability in the course of the disease which are distinct features separating from other solid tumors. These features prevent the development and standardization of non-surgical treatment models of malignant melanoma. Although there is a large number of chemotherapeutic agents used in the treatment of metastatic malignant melanoma, it hasn’t been demonstrated the survival advantage of adjuvant treatment with chemotherapeutic agents. Because of the different clinical course of malignant melanoma, the disease is thought to be closely associated with immune system. Therefore, immunomodulatory therapy models were developed. Mistletoe stimulates the immune system by increasing the number and activity of dendritic cells, thus it has been shown to effect on tumor growth and metastasis of malignant melanoma patient. Outlined in this review are the recent developments in the understanding the role of mistletoe as a complementary therapy for malignant melanoma. J Clin Exp Invest 2014; 5 (1): 145-152
topic Malignant melanoma
mistletoe
url http://www.jceionline.org/upload/sayi/20/JCEI-00859.pdf
work_keys_str_mv AT esinsakallıcetin mistletoeinthetreatmentofmalignantmelanoma
AT pınaraslankosar mistletoeinthetreatmentofmalignantmelanoma
AT nurtenozcelik mistletoeinthetreatmentofmalignantmelanoma
_version_ 1721180013910294528